You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-negative or not amplified

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Beijing (Pyrotinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Beijing, Beijing, China
    Peking Union Medical College
Feb 20, 2023

HER2 Negative Breast Cancer Not Immediately Operated Trial (Ribociclib Oral Tablet)

Not yet recruiting
  • HER2 Negative Breast Cancer Not Immediately Operated
  • Ribociclib Oral Tablet
  • (no location specified)
Dec 16, 2022

HER2 Mutation-Related Tumors, HER2 Amplified Solid Tumors Trial in Miami Beach, Kansas City (ARX788)

Withdrawn
  • HER2 Mutation-Related Tumors
  • HER2 Amplified Solid Tumors
  • Miami Beach, Florida
  • +1 more
Apr 22, 2022

HER2-low in Unresectable and/or Metastatic Breast Cancer

Not yet recruiting
  • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
    • (no location specified)
    Nov 6, 2023

    HER2-low in Metastatic Breast Cancer Patients

    Not yet recruiting
    • HER2-negative
      • (no location specified)
      Nov 9, 2023

      Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

      Active, not recruiting
      • Hormone-receptor-positive Breast Cancer
      • +2 more
      • No drug
      • Cambridge, Massachusetts
        ConcertAI database
      Sep 8, 2023

      Breast Tumors Trial in Guangzhou (procedure, drug, biological)

      Recruiting
      • Breast Neoplasms
      • Sentinel Lymph Node Biopsy (SLNB)
      • +7 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      Nov 2, 2023

      HER2 Amplified Breast Cancer Trial in Lisboa (Neratinib, Capecitabine, Loperamide)

      Completed
      • HER2 Amplified Breast Cancer
      • Lisboa, Portugal
        Hospital CUF Descobertas
      Apr 4, 2022

      Breast Tumors Trial in Guangzhou (procedure, drug, biological)

      Recruiting
      • Breast Neoplasms
      • Sentinel Lymph Node Biopsy (SLNB)
      • +7 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      Jul 31, 2023

      Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (proton plus carbon ion radiotherapy)

      Recruiting
      • Triple Negative Breast Cancer
      • HER2-positive Breast Cancer
      • proton plus carbon ion radiotherapy
      • Shanghai, China
        Shanghai Proton and Heavy Ion center
      Jan 11, 2023

      Breast Tumors Trial in Guangzhou (procedure, drug, biological)

      Recruiting
      • Breast Neoplasms
      • Surgery for harvesting tumor-draining lymph nodes
      • +6 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      Nov 2, 2023

      Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer Trial in Guangzhou (Fluzoparib, Fluzoparib+Camrelizumab)

      Recruiting
      • Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
      • Guangzhou, Guangdong, China
        Sun-yat sen university cancer center
      Jan 27, 2023

      Breast Cancer Trial in Xi'an (metronomic oral vinorelbine plus anlotinib)

      Recruiting
      • Breast Cancer
      • metronomic oral vinorelbine plus anlotinib
      • Xi'an, Shaanxi, China
        Xi'an International Medical Center Hospital
      Aug 27, 2023

      Breast Tumors Trial in Guangzhou (procedure, drug, biological)

      Recruiting
      • Breast Neoplasms
      • Surgery for harvesting tumor-draining lymph nodes
      • +8 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      Jul 31, 2023

      Breast Cancer Trial in Tianjin (Dalcelli?Exemestane?Gosserine, Docetaxel for injection?Epirubicin HCl for

      Recruiting
      • Breast Cancer
      • Tianjin, Tianjin, China
        Jie Ge
      Aug 20, 2023

      Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

      Recruiting
      • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
      • dalpiciclib; fluvestrant; compound gossypol acetate tablets
      • Hangzhou, Zhejiang, China
        zhejiangCH
      Nov 9, 2023

      Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

      Recruiting
      • Hormone Receptor Positive HER-2 Negative Breast Cancer
      • Shanghai, Shanghai, China
        Breast cancer institute of Fudan University Cancer Hospital
      Jun 12, 2023

      Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

      Not yet recruiting
      • Breast Cancer
      • Disitamab Vedotin+Anlotinib
      • (no location specified)
      Aug 14, 2023

      Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

      Not yet recruiting
      • Estrogen-receptor-positive Breast Cancer
      • +3 more
      • elacestrant, palbociclib, abemaciclib, ribociclib
      • Chicago, Illinois
        Northwestern University
      Sep 25, 2023

      Germline BRCA-mutated HER2-negative Breast Cancer Trial in Beijing (Camrelizumab+Fluzoparib)

      Enrolling by invitation
      • Germline BRCA-mutated HER2-negative Breast Cancer
      • Beijing, Beijing, China
        Breast Cancer, Peking University People's Hospital
      Nov 14, 2022

      Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer Trial in New Haven (Dapagliflozin 10mg)

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • Dapagliflozin 10mg
      • New Haven, Connecticut
        Yale Cancer Center Smilow Cancer Hospital
      Aug 3, 2023

      Breast Cancer Trial (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Breast Cancer
      • Trastuzumab Deruxtecan
      • (no location specified)
      Jul 10, 2023

      Breast Tumors, Malignant Tumor of Breast Trial in Dallas (Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg)

      Recruiting
      • Breast Neoplasms
      • Malignant Neoplasm of Breast
      • Dallas, Texas
        10 sites incl TX, WA, VA, and NV
      May 16, 2022

      Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Triple-Negative Breast Cancer
      • Trastuzumab Deruxtecan
      • Shanghai, Shanghai, China
        Breast cancer institute of Fudan University Cancer Hospital
      Jul 12, 2023

      Invasive Breast Cancer Trial in Milwaukee (Cemiplimab, Paclitaxel, Carboplatin (not mandatory))

      Recruiting
      • Invasive Breast Cancer
      • Milwaukee, Wisconsin
        Froedtert Hospital & Medical College of Wisconsin
      Apr 1, 2022